We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Imunon Inc (IMNN) USD0.01

Sell:$0.79 Buy:$0.80 Change: $0.0243 (3.07%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.80
Change: $0.0243 (3.07%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.80
Change: $0.0243 (3.07%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Contact details

Address:
997 Lenox Dr Ste 100
LAWRENCEVILLE
08648
United States
Telephone:
+1 (609) 8969100
Website:
https://imunon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMNN
ISIN:
US15117N6022
Market cap:
$11.82 million
Shares in issue:
14.50 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Tardugno
    Executive Chairman of the Board
  • Stacy Lindborg
    President, Chief Executive Officer, Director
  • David Gaiero
    Chief Financial Officer
  • Khursheed Anwer
    Executive Vice President, Chief Scientific Officer
  • Sebastien Hazard
    Executive Vice President, Chief Medical Officer
  • Susan Eylward
    General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.